Clinical Trials
12 trialsNCT04038619 2026-03-20
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT02057133 2026-01-26
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Eli Lilly and Company
Phase 1 Active not recruiting
NCT05520723 2025-12-04
PRIMED
MedSIR
Phase 2 Completed
NCT06892093 2025-09-08
Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase NA Recruiting
NCT03094052 2025-06-26
Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib
University of California, San Francisco
Phase 2 Completed
NCT05252988 2025-04-01
DIANER
Spanish Breast Cancer Research Group
Phase 2 Active not recruiting
NCT04172597 2024-03-13
A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies
Spectrum Pharmaceuticals, Inc
Phase 2 Terminated
NCT04366713 2023-02-10
A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib
Puma Biotechnology, Inc.
Phase 2 Completed
NCT05252546 2022-12-23
Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT02400476 2022-05-06
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide
Puma Biotechnology, Inc.
Phase 2 Completed
NCT04736186 2021-02-03
Prevention and Treatment of Pyrrolitinib-associated Diarrhea
Tianjin Medical University Cancer Institute and Hospital
Phase 2/3 Unknown
NCT02441946 2020-06-17
neoMONARCH
Eli Lilly and Company
Phase 2 Completed